Modality.AI measures what patients say and do in clinical research.
Greetings ,
As we move into this new season, we are pleased to share recent publications and highlight upcoming opportunities to engage in person. Working with biopharma and academic partners, we continue to demonstrate how speech and video analytics deliver reliable outcome measures that enhance trial efficiency and sensitivity while reducing patient burden.
Announcing our Collaboration with Ametris
In July, we launched a strategic partnership with Ametris (formerly Actigraph) to expand remote measures in neurodegenerative clinical trials (Press Release). This month, Ametris will host a webinar to discuss "Redefining ALS Clinical Endpoints: Unlocking the Potential of Digital Health Technologies". Modality CEO, David “DSO” Suendermann-Oeft, will join a multidisciplinary panel to discuss our work in accelerating the adoption of digital measures.
Date: Tuesday, October 14th
Time: 12 PM ET, 9 AM PT
Register: https://ametris.com/digital-health-monthly/als-clinical-endpoints
Opportunities to Connect in Person
If you or a colleague will be attending any of the following, please make a time to meet.
New Publications from our Research Team
Over the past few months, members of our team have presented new publications at international conferences, including the Ametris Digital Data Summit, Text Speech Dialog (TSD), IEEE's International Conference on Digital Health (ICDH), and Interspeech. These additions join more than one hundred peer-reviewed publications featured on our website.
SCHIZOPHRENIA: https://modality.ai/publications/schizophrenia
- The Advantage of Combining Health Information From Different Modalities in Objective Remote Assessment of Schizophrenia
- Uncovering Emotional Dynamics in Schizophrenia through Interpretable Multimodal Analysis (🏆 This poster earned the Best Poster Award)
- Remote Assessment of Emotion Dynamics in Schizophrenia using a Multimodal Dialog System
PARKINSON'S DISEASE: https://modality.ai/publications/parkinsons-disease
- Leveraging Fine-Tuned State-of-the-Art LLMs for Symptom Classification of Patient-Reported Problems in Parkinson's Disease
- Toward Quantifying How The Burden of Problems Reported By Patients Evolves in Parkinson's Disease: An Exploratory Analysis
ALS: https://modality.ai/publications/als
- Multimodal Speech-Based Biomarkers Outperform the ALS Functional Rating Scale in Predicting Individual Disease Progression in ALS
MCI: https://modality.ai/publications/dementia
- An Exploration of Interpretable Deep Learning Models for the Assessment of Mild Cognitive Impairment
MODALITY PLATFORM: https://modality.ai/publications/modality-platform
- Accessible Real-time Eye-gaze Tracking for Neurocognitive Health Assessment: A Multimodal Web-based Approach
In Closing
As always, we would welcome the opportunity to demonstrate the unique advantages of including Modality's automated speech and video analytics in your research study or trial. It's easy to find a convenient time via our shared calendar.
We look forward to connecting, whether in person or online.
Regards,
David Fox
CBO and Co-Founder, Modality.AI
Follow Modality.AI: https://www.linkedin.com/company/modality-ai